Modlich, Ute

Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity

Braun, C. J., Boztug, K., Paruzynski, A., Witzel, M., Schwarzer, A., Rothe, M., Modlich, U., Beier, R., Göhring, G., Steinemann, D., et al. (2014) · Science Translational Medicine

Virus-based gene therapy researchImmunodeficiency and Autoimmune Disorders

Cited by 562

Insertional Transformation of Hematopoietic Cells by Self-inactivating Lentiviral and Gammaretroviral Vectors

Modlich, U., Navarro, S., Zychlinski, D., Maetzig, T., Knoess, S., Brugman, M. H., Schambach, A., Charrier, S., Galy, A., Thrasher, A. J., et al. (2009) · Molecular Therapy

Virus-based gene therapy researchCRISPR and Genetic Engineering

Cited by 387

Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors

Zychlinski, D., Schambach, A., Modlich, U., Maetzig, T., Meyer, J., Grassman, E., Mishra, A., & Baum, C. (2008) · Molecular Therapy

Virus-based gene therapy researchCRISPR and Genetic Engineering

Cited by 271

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., et al. (2013) · Blood

Acute Myeloid Leukemia ResearchGlioma Diagnosis and Treatment

Cited by 210

Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy

Rothe, M., Modlich, U., & Schambach, A. (2014) · Current Gene Therapy

Virus-based gene therapy researchCRISPR and Genetic Engineering

Cited by 110